Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology...
Clinical Trial
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline BRUSSELS and SAN FRANCISCO, May...
eCOA Solutions Market worth US$4.78 billion by 2030 with 16.1% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., May 19, 2025 /PRNewswire/ -- The global eCOA solution market, valued at US$1.94 billion in 2024, is forecasted...
Vitalograph and Thorasys Forge Strategic Partnership to Expand Respiratory Diagnostics with Launch of Tremoflo® C2 Oscillometer
SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- At the American Thoracic Society (ATS) Annual Conference, Vitalograph and Thorasys announced a...
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced...
Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer
Seasoned biopharma executive brings more than twenty years of business development, strategy, and operational expertise to Arbor’s leadership teamCAMBRIDGE, Mass.,...
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related...
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as...
Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria...
Lifeward Names Mark Grant as New CEO
Industry veteran brings 30 years of commercial leadership experienceMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward...
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first...
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered...
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28,...
Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model
--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein...
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19,...
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR...
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through...
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements...
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary...
Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000...